ANDROMEDA Strain: Full Data Published From Multaq Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Details show death rates that led to Sanofi study's halt.
You may also be interested in...
Sanofi Halts Multaq Trial Early Due To Cardiac Events
The Phase IIIb trial was in patients who had had atrial fibrillation for at least six months; an earlier trial in heart failure also was terminated because of increased risk.
Sanofi Halts Multaq Trial Early Due To Cardiac Events
The Phase IIIb trial was in patients who had had atrial fibrillation for at least six months; an earlier trial in heart failure also was terminated because of increased risk.
Sanofi Halts Multaq Trial Early Due To Cardiac Events
Sanofi is facing another safety issue with its antiarrhythmic drug Multaq (dronedarone) with the termination of a Phase IIIb clinical trial in patients with permanent atrial fibrillation due to an increase in cardiovascular events.